75% Upside For LLY Stock?

Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company’s immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.

This broad-based expansion is why the upside case centers on revenue. The core franchises are demonstrating significant momentum, independent of the incretin wave. The question is how much new growth can be layered on top of this already powerful base.

That’s the story. The question is whether it’s strong enough to deliver real upside from here, or whether today’s price has already absorbed most of the optimism. Mostly yes. A conservative 3-year scenario points to roughly 75% of upside potential in LLY, and the operational story carries it. The earnings line is moving in the right direction, but a softer multiple is set to chew a meaningful chunk of that out before it reaches the stock. Here is the operational picture the math sits on top of:

*LTM: Last Twelve Months

How Compounding Builds The Upside

Revenue compounds at 30.0% annually, taking the top line from $72.2B to $158.7B over three years. That is a step down from the LTM 47.4% pace, because today’s acceleration is unlikely to extrapolate cleanly over three years.

Margins ease from 35.0% to 31.3% as today’s LTM gives back a little to the longer-run average. Together, that takes earnings from $25.3B to roughly $49.7B, a 97% jump.

Here is where the stock and the earnings lines diverge. LLY’s P/E already sits at 38.2x, below its 3-year average of 67.2x. The scenario trims it further to 34.0x, because a slower forward growth rate no longer supports even today’s multiple. That single move chews roughly 11% out of what the earnings growth would otherwise have delivered. Apply the lower multiple to the higher earnings, and the stock lands near $1889.51, a market cap of $1.7T against $965.0B today. That is roughly 75% above where the stock trades now. The earnings line is doing the work; the multiple is taking a meaningful cut of it before it reaches the share price.

Has revenue compounding been the lever driving LLY’s recent move? See the lever breakdown. Curious how this exact compounding math looks when applied to tech instead of pharma? Read: Can META Stock Compound Its Way Higher?

What Could Accelerate The Top Line

The next major revenue inflection comes from unlocking a vast new patient population. CMS’s Medicare GLP-1 bridge program will begin no later than July 1, 2026, opening access for millions of seniors. By capping out-of-pocket costs at $50 per month, the program removes a significant barrier to adoption.

What Could Slow It Down

The explosive volume growth, however, comes with a trade-off. Management concedes that price will be a headwind in the low to mid-teens for the full year. This pressure is already visible, as U.S. prices declined by 7% in the quarter, suggesting the current trajectory is at a cyclical peak.

Is The Compounding Real?

For the case to play out, revenue has to keep compounding near 30.0%, a step down from today’s 47.4% but still firmly positive. The multiple is the other moving piece: the case trims it from 38.2x to 34.0x to reflect a slower forward growth rate, not any re-rating. If growth holds up better than projected, that compression reverses, and the upside is larger. A cyclical caveat sits underneath all of this: today’s LTM numbers come off a peak, not a sustainable rate, so a revert toward the 3-year baseline would lower the earnings base before the rest of the math even starts.

New Medicare access provides a clear path to more volume, making the expected pricing headwind a manageable part of the growth story.

Should You Invest In Eli Lilly?

A careful 3-year case on a single name is still a concentrated bet, as historical volatility across past market crises shows. Investors who build analyses like this on individual positions often want the same framework running across a diversified book, partly for discipline, partly because even the cleanest single-stock thesis can break for reasons the math does not capture.

The Trefis High Quality (HQ) Portfolio combines analytical rigor with a forward-looking view across 30 stocks, with a consistent selection framework and a sizing and re-balancing discipline designed to deliver upside without the single-name risk you just read through here.

By selecting 30 high-conviction stocks, the HQ strategy has historically outpaced the S&P 500, S&P Mid-cap, and Russell 2000.